349 related articles for article (PubMed ID: 14581355)
41. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?
Stallings RL; Howard J; Dunlop A; Mullarkey M; McDermott M; Breatnach F; O'Meara A
Cancer Genet Cytogenet; 2003 Jan; 140(2):133-7. PubMed ID: 12645651
[TBL] [Abstract][Full Text] [Related]
42. Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain.
Schleiermacher G; Bourdeaut F; Combaret V; Picrron G; Raynal V; Aurias A; Ribeiro A; Janoueix-Lerosey I; Delattre O
Oncogene; 2005 May; 24(20):3377-84. PubMed ID: 15735707
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
44. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
Henrich KO; Fischer M; Mertens D; Benner A; Wiedemeyer R; Brors B; Oberthuer A; Berthold F; Wei JS; Khan J; Schwab M; Westermann F
Clin Cancer Res; 2006 Jan; 12(1):131-8. PubMed ID: 16397034
[TBL] [Abstract][Full Text] [Related]
45. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
Vandesompele J; Baudis M; De Preter K; Van Roy N; Ambros P; Bown N; Brinkschmidt C; Christiansen H; Combaret V; Lastowska M; Nicholson J; O'Meara A; Plantaz D; Stallings R; Brichard B; Van den Broecke C; De Bie S; De Paepe A; Laureys G; Speleman F
J Clin Oncol; 2005 Apr; 23(10):2280-99. PubMed ID: 15800319
[TBL] [Abstract][Full Text] [Related]
46. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
47. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
[TBL] [Abstract][Full Text] [Related]
48. Numerical abnormalities of chromosomes 17 and 18 in sporadic colorectal cancer: Incidence and correlation with clinical and biological findings and the prognosis of the disease.
Garcia J; Duran A; Tabernero MD; Garcia Plaza A; Flores Corral T; Najera ML; Gomez-Alonso A; Orfao A
Cytometry B Clin Cytom; 2003 Jan; 51(1):14-20. PubMed ID: 12500293
[TBL] [Abstract][Full Text] [Related]
49. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
50. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
[TBL] [Abstract][Full Text] [Related]
51. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
[TBL] [Abstract][Full Text] [Related]
52. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH.
Selzer RR; Richmond TA; Pofahl NJ; Green RD; Eis PS; Nair P; Brothman AR; Stallings RL
Genes Chromosomes Cancer; 2005 Nov; 44(3):305-19. PubMed ID: 16075461
[TBL] [Abstract][Full Text] [Related]
53. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group.
Lastowska M; Cotterill S; Pearson AD; Roberts P; McGuckin A; Lewis I; Bown N
Eur J Cancer; 1997 Sep; 33(10):1627-33. PubMed ID: 9389925
[TBL] [Abstract][Full Text] [Related]
54. Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA.
Combaret V; Bréjon S; Iacono I; Schleiermacher G; Pierron G; Ribeiro A; Bergeron C; Marabelle A; Puisieux A
Pediatr Blood Cancer; 2011 May; 56(5):757-61. PubMed ID: 21370407
[TBL] [Abstract][Full Text] [Related]
55. Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.1.
Spieker N; Beitsma M; Van Sluis P; Chan A; Caron H; Versteeg R
Genes Chromosomes Cancer; 2001 Jun; 31(2):172-81. PubMed ID: 11319804
[TBL] [Abstract][Full Text] [Related]
56. Analysis of genomic imprinting at 1p35-36 in neuroblastoma.
Hogarty MD; Maris JM; White PS; Guo C; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):52-5. PubMed ID: 11464906
[TBL] [Abstract][Full Text] [Related]
57. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
[TBL] [Abstract][Full Text] [Related]
58. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
[TBL] [Abstract][Full Text] [Related]
59. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
Maris JM; Guo C; White PS; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):24-7. PubMed ID: 11464895
[TBL] [Abstract][Full Text] [Related]
60. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.
Godfried MB; Veenstra M; v Sluis P; Boon K; v Asperen R; Hermus MC; v Schaik BD; Voûte TP; Schwab M; Versteeg R; Caron HN
Oncogene; 2002 Mar; 21(13):2097-101. PubMed ID: 11960382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
